The case for biosimilars–a payer’s perspective
Abstract:Â Biosimilars have the potential for making savings in healthcare costs, and with resource allocation, if competition is permitted at the level of treatment induction. Submitted:Â 24 August 2012;Â Revised:Â 17 January 2013;Â Accepted:Â 4 February 2013;Â Published online first:Â 13 February 2013 The last decade or so has seen the introduction of many truly innovative biological pharmaceuticals that have had a […]